Literature DB >> 3309859

Leprechaunism: in vitro insulin action despite genetic insulin resistance.

M E Geffner1, S A Kaplan, N Bersch, B M Lippe, W G Smith, R A Nagel, T V Santulli, C H Li, D W Golde.   

Abstract

We recently identified a female leprechaun infant with marked hyperinsulinemia [as high as 10,975 microU/ml (78,746 pmol/liter)], presumably secondary to insulin resistance. She had two physical findings suggestive of possible insulin action: cystic ovarian enlargement with gonadotropin-independent steroid secretion and persistent, severe myocardial hypertrophy. To examine the pathophysiology of this disorder we measured the in vitro sensitivity to insulin and other growth factors of erythroid progenitors and a T-lymphoblast cell line derived from her peripheral blood. Resistance to insulin was demonstrated by failure of her circulating erythroid progenitor cells to augment proliferation in response to physiologic concentrations of insulin (1-10 ng/ml). An immortalized T lymphoblast cell line was established by transforming the cells with the human retrovirus human T cell leukemia virus II. This cell line showed little or no response to physiologic concentrations of insulin contrary to consistently observed stimulation of colony formation by cell lines similarly derived from normals. The patient's T lymphoblasts, however, showed normal sensitivity to insulin-like growth factor I. In response to supraphysiologic insulin concentrations (25-1000 ng/ml), leprechaun T lymphoblasts showed significant augmentation of colony formation (peak 189% above baseline at 50 ng/ml); normal T lymphoblasts also showed responsiveness at these high insulin concentrations. Preincubation with a monoclonal antibody against the insulin-like growth factor I receptor (alpha IR-3 at 5000 ng/ml) blocked the in vitro effect of physiologic concentrations of insulin-like growth factor and supraphysiologic concentrations of insulin on leprechaun and control T lymphoblast colony formation, but had no clear effect upon the response to physiologic insulin concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309859     DOI: 10.1203/00006450-198709000-00010

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

Review 1.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

2.  Reversible obstructive hypertrophic cardiomyopathy in the Beckwith-Wiedemann syndrome.

Authors:  C A Ryan; M H Boyle; G W Burggraf
Journal:  Pediatr Cardiol       Date:  1989       Impact factor: 1.655

3.  A syndrome of insulin resistance resembling leprechaunism in five sibs of consanguineous parents.

Authors:  L I al-Gazali; M Khalil; K Devadas
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

4.  Two Novel Variants and One Previously Reported Variant in the Insulin Receptor Gene in Two Cases with Severe Insulin Resistance Syndrome.

Authors:  Aydilek Dagdeviren Cakir; Said Saidov; Hande Turan; Serdar Ceylaner; Yavuz Özer; Tufan Kutlu; Oya Ercan; Olcay Evliyaoglu
Journal:  Mol Syndromol       Date:  2020-03-18

5.  Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance.

Authors:  Isabel Huang-Doran; Alexandra B Kinzer; Mercedes Jimenez-Linan; Kerrie Thackray; Julie Harris; Claire L Adams; Marc de Kerdanet; Anna Stears; Stephen O'Rahilly; David B Savage; Phillip Gorden; Rebecca J Brown; Robert K Semple
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

6.  Two novel mutations identified in familial cases with Donohue syndrome.

Authors:  Tzipora C Falik Zaccai; Limor Kalfon; Aharon Klar; Mordechai Ben Elisha; Haggit Hurvitz; Galina Weingarten; Emelia Chechik; Vered Fleisher Sheffer; Raid Haj Yahya; Gal Meidan; Eva Gross-Kieselstein; Dvora Bauman; Sylvia Hershkovitz; Yuval Yaron; Avi Orr-Urtreger; Efrat Wertheimer
Journal:  Mol Genet Genomic Med       Date:  2013-11-14       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.